Search research articles
Contact Us
Filters
Showing results (61-70 of 78) with videos related to
Page
of 8
Sort By:
Biochimie
|
August 23, 2015
Cross-reactivity of anti-PLA2R1 autoantibodies to rabbit and mouse PLA2R1 antigens and development of two novel ELISAs with different diagnostic performances in idiopathic membranous nephropathy
Barbara Seitz-Polski, Guillaume Dolla, Christine Payré, et al.
Journal of the American Society of Nephrology : JASN
|
November 15, 2015
Epitope Spreading of Autoantibody Response to PLA2R Associates with Poor Prognosis in Membranous Nephropathy
Barbara Seitz-Polski, Guillaume Dolla, Christine Payré, et al.
Kidney International Reports
|
February 5, 2024
Optimization of Rituximab Therapy in Adult Patients With PLA2R1-Associated Membranous Nephropathy With Artificial Intelligence
Alexandre Destere, Maxime Teisseyre, Diane Merino, et al.
Biorxiv : the Preprint Server for Biology
|
July 19, 2024
p16<sup>High</sup> immune cell - controlled disease tolerance as a broad defense and healthspan extending strategy
Francisco Triana-Martinez, Alessandra Pierantoni, Daisy Graca, et al.
Clinical Kidney Journal
|
May 5, 2025
Artificial intelligence to guide rituximab therapy in patients with phospholipase A2 receptor-associated membranous nephropathy
Maxime Teisseyre, Alexandre Destere, Marion Cremoni, et al.
The New England Journal of Medicine
|
November 14, 2014
Thrombospondin type-1 domain-containing 7A in idiopathic membranous nephropathy
Nicola M Tomas, Laurence H Beck, Catherine Meyer-Schwesinger, et al.
Kidney International Reports
|
August 15, 2025
Anti-Rituximab Antibodies Occurrence and Clinical Outcomes in Patients With Primary Membranous Nephropathy
Marco Allinovi, Maxime Teisseyre, Matteo Accinno, et al.
Ebiomedicine
|
November 11, 2021
Safety and cross-variant immunogenicity of a three-dose COVID-19 mRNA vaccine regimen in kidney transplant recipients
Filippo Massa, Marion Cremoni, Alexandre Gérard, et al.
Kidney International Reports
|
April 14, 2025
Obinutuzumab and Ofatumumab are More Effective Than Rituximab in the Treatment of Membranous Nephropathy Patients With Anti-Rituximab Antibodies
Maxime Teisseyre, Marco Allinovi, Vincent Audard, et al.
Immunity
|
March 27, 2026
p16<sup>High</sup>-expressing immune cells control disease tolerance as a defense and health span-extending strategy
Francisco Triana-Martinez, Alessandra Pierantoni, Daisy Graca, et al.
Page
of 8
Search research articles
Search
Showing results (61-70 of 78) with videos related to
Sort By:
Page
of 8
Biochimie
|
August 23, 2015
Cross-reactivity of anti-PLA2R1 autoantibodies to rabbit and mouse PLA2R1 antigens and development of two novel ELISAs with different diagnostic performances in idiopathic membranous nephropathy
Barbara Seitz-Polski, Guillaume Dolla, Christine Payré, et al.
Journal of the American Society of Nephrology : JASN
|
November 15, 2015
Epitope Spreading of Autoantibody Response to PLA2R Associates with Poor Prognosis in Membranous Nephropathy
Barbara Seitz-Polski, Guillaume Dolla, Christine Payré, et al.
Kidney International Reports
|
February 5, 2024
Optimization of Rituximab Therapy in Adult Patients With PLA2R1-Associated Membranous Nephropathy With Artificial Intelligence
Alexandre Destere, Maxime Teisseyre, Diane Merino, et al.
Biorxiv : the Preprint Server for Biology
|
July 19, 2024
p16<sup>High</sup> immune cell - controlled disease tolerance as a broad defense and healthspan extending strategy
Francisco Triana-Martinez, Alessandra Pierantoni, Daisy Graca, et al.
Clinical Kidney Journal
|
May 5, 2025
Artificial intelligence to guide rituximab therapy in patients with phospholipase A2 receptor-associated membranous nephropathy
Maxime Teisseyre, Alexandre Destere, Marion Cremoni, et al.
The New England Journal of Medicine
|
November 14, 2014
Thrombospondin type-1 domain-containing 7A in idiopathic membranous nephropathy
Nicola M Tomas, Laurence H Beck, Catherine Meyer-Schwesinger, et al.
Kidney International Reports
|
August 15, 2025
Anti-Rituximab Antibodies Occurrence and Clinical Outcomes in Patients With Primary Membranous Nephropathy
Marco Allinovi, Maxime Teisseyre, Matteo Accinno, et al.
Ebiomedicine
|
November 11, 2021
Safety and cross-variant immunogenicity of a three-dose COVID-19 mRNA vaccine regimen in kidney transplant recipients
Filippo Massa, Marion Cremoni, Alexandre Gérard, et al.
Kidney International Reports
|
April 14, 2025
Obinutuzumab and Ofatumumab are More Effective Than Rituximab in the Treatment of Membranous Nephropathy Patients With Anti-Rituximab Antibodies
Maxime Teisseyre, Marco Allinovi, Vincent Audard, et al.
Immunity
|
March 27, 2026
p16<sup>High</sup>-expressing immune cells control disease tolerance as a defense and health span-extending strategy
Francisco Triana-Martinez, Alessandra Pierantoni, Daisy Graca, et al.
Page
of 8